


# Analytical Methods

Accepted Manuscript

This article can be cited before page numbers have been issued, to do this please use: Y. Xu, S. Yang, S. Ding, T. Xu, J. Ge, W. Xiao, L. Zhu and G. Feng, *Anal. Methods*, 2026, DOI: 10.1039/D5AY02047F.




This is an Accepted Manuscript, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this Accepted Manuscript with the edited and formatted Advance Article as soon as it is available.

You can find more information about Accepted Manuscripts in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this Accepted Manuscript or any consequences arising from the use of any information it contains.



500x348mm (96 x 96 DPI)

## ARTICLE

## Development and Application of a Tetra-ARMS PCR Assay for Detecting Indel Polymorphisms in the Bovine *PRNP* Gene

Ye Xu<sup>a</sup>, Siyu Yang<sup>a</sup>, Siling Ding<sup>a</sup>, Ting Xu<sup>a</sup>, Jian Ge<sup>a</sup>, Weiming Xiao<sup>b</sup>, Like Zhu<sup>b</sup>, Feng Guan<sup>\*a</sup>

Received 00th January 20xx,  
Accepted 00th January 20xx

DOI: 10.1039/x0xx00000x

Insertion/deletion (indel) polymorphisms in the promoter region (23 bp) and intron 1 (12 bp) of the bovine *PRNP* gene influence gene expression and susceptibility to bovine spongiform encephalopathy (BSE). Conventional detection strategies dependent on DNA sequencing are cumbersome and costly. A tetra-primer amplification refractory mutation system PCR (Tetra-ARMS PCR) assay was developed which can be able to enable efficient and cost-effective genotyping of each indel locus. Optimized tetra-ARMS PCR primers and multiplex conditions allowed electrophoretic genotyping of the 23 bp indel via the size and presence of 422 bp, 259 bp, and 193 bp amplicons, whereas the 12 bp indel was genotyped based on the size and presence of 598 bp, 472 bp, and 153 bp fragments. Furthermore, the compatibility of these primer sets was preliminarily investigated, demonstrating the potential for co-amplification in a single-tube multiplex format. Validation against Sanger sequencing using 62 randomly selected cattle-derived retail samples demonstrated complete concordance. This straightforward, specific and cost-effective method requires only conventional PCR instrumentation, thereby establishing a robust and accessible platform for *PRNP*-assisted breeding and cattle product genotyping.

### 1 Introduction

Bovine spongiform encephalopathy (BSE), commonly known as 'mad cow disease', is a fatal neurodegenerative disorder resulting from conformational aberrations in the scrapie prion protein (*PrP*<sup>Sc</sup>)<sup>1</sup>. Initially identified in the United Kingdom in 1986, BSE later underwent rapid global dissemination, causing devastating livestock losses and precipitating an international public health crisis<sup>2-4</sup>. Although the global incidence of BSE has substantially declined following the implementation of control measures (e.g., prohibitions on ruminant-derived

feed), elucidating its pathogenesis and establishing effective management strategies remain significant challenges<sup>5-7</sup>. The pathogenic isoform *PrP*<sup>Sc</sup> exhibits pronounced resistance to conventional disinfection and thermal decontamination<sup>8-10</sup>. Furthermore, multiple transmission routes of BSE are documented, including milk and meat products<sup>11, 12</sup>, while environmental prion contamination may constitute secondary vectors<sup>13, 14</sup>. Collectively, these effective factors impede eradication efforts for this disease<sup>13, 15-17</sup>. As the primary determinant of prion protein expression, polymorphisms in the bovine prion protein gene (*PRNP*) modulate its susceptibility to BSE and its heritability<sup>18-22</sup>. Following the bovine *PRNP* gene sequencing in 2001<sup>6, 20, 23, 24</sup>, studies have demonstrated that 23 bp indel in the promoter region and 12 bp indel in the intronic region are significantly associated with BSE resistance,

<sup>a</sup> College of Life Sciences, China Jiliang University, Hangzhou 310018, China.

<sup>b</sup> Key Laboratory of Dairy Cow Genetic Improvement and Milk Quality Research of Zhejiang Province, Wenzhou 325000, China.

## 1 ARTICLE

2 thereby informing DNA marker assisted selection of resistant  
 3 individuals<sup>7, 18, 22, 25-27</sup>. Current strategies encompass *PRNP*  
 4 gene editing to enhance resistance in cattle breeding<sup>28</sup>.  
 5 Consequently, detection of *PRNP* polymorphisms in any locus  
 6 for BSE risk assessment provides assisted molecular markers  
 7 for breeding programs, enabling strategic selection of resistant  
 8 populations and guiding containment policies—imperative for  
 9 safeguarding livestock industries and public health.

10  
 11 Current DNA genotyping of the 23 bp and 12 bp indel  
 12 polymorphisms in bovine *PRNP* gene primarily employs Sanger  
 13 sequencing<sup>22, 29-34</sup>, PCR-RFLP analysis<sup>35</sup>, quantitative PCR  
 14 (qPCR)<sup>36</sup>, next-generation sequencing (NGS)<sup>37</sup>, and microarray  
 15 genotyping<sup>38</sup>, et al. These methodologies are constrained by  
 16 protracted processing times, elevated costs, and technical  
 17 limitations, notably incomplete restriction enzyme digestion.  
 18 Specifically, Sanger sequencing, despite providing precise  
 19 sequence resolution, incurs high per-sample costs; PCR-RFLP is  
 20 susceptible to interpretive errors owing to partial enzymatic  
 21 cleavage, compromising its reliance on restriction site  
 22 specificity; NGS, although permitting high-throughput multi-  
 23 locus analysis, requires substantial instrumentation investment  
 24 and sophisticated bioinformatics assay, thereby precluding  
 25 routine diagnostics in resource-limited settings. Compared to  
 26 the conventional detection methods mentioned above,  
 27 amplification refractory mutation system PCR (ARMS-PCR),  
 28 which exploits deliberate primer-template mismatches and  
 29 constitutes a robust DNA analysis platform featuring  
 30 operational simplicity, elimination of enzymatic  
 31 digestion/fluorescent probes, cost-effectiveness, broad  
 32 applicability, visual electrophoretic resolution, and inherent  
 33 heterozygote discrimination<sup>39-43</sup>. Subsequent to its inception,  
 34 the tetra-primer ARMS-PCR incorporated internal control  
 35 primers to increase its accuracy, and has been widely applied  
 36 to species identification and SNP genotyping across diverse  
 37 biological systems<sup>44-49</sup>, thus showing exceptional procedural  
 38 efficiency and accessibility for routine genetic screening.

39 A Tetra-ARMS PCR-based DNA mismatch detection  
 40 system was established in this study through optimized  
 41 designed primers for the rapid and accurate genotyping of the  
 42 23 bp and 12 bp indel polymorphisms in the bovine *PRNP*  
 43 gene. This study developed and validated two independent  
 44 Tetra-ARMS PCR assays, and explored their potential for  
 45 integration into a multiplex system. This assay enhances  
 46 genotyping efficiency, broadens methodological capabilities  
 47 for indel screening, and thereby provides technical support for  
 48 DNA marker-assisted breeding programs and disease risk  
 49 assessment in cattle populations.

## 2 Materials and Methods

View Article Online

DOI: 10.1039/D5AY02047F

## 2.1 Sample Sources and DNA Extraction

A total of 230 genomic DNA samples were stored in the laboratory and were isolated from blood samples of Holstein cattle (n = 200), Yellow cattle (n = 10), and Wenzhou water buffalo (n = 20). Additionally, commercial specimens (fresh milk, beef, milk powder, cheese; n = 62) were purchased from retail markets, representing diverse production batches and dates. The blood samples of Holstein cattle and Wenzhou water buffalo were provided by the Key Laboratory of Dairy Cow Genetic Improvement and Milk Quality Research of Zhejiang Province, while those of Yellow cattle were from the Dairy Cattle Breeding Farm of Shandong Academy of Agricultural Sciences. Genomic DNA was extracted using a commercial Animal Tissue DNA Extraction Kit (Hangzhou Xinjing Biotechnology Co., China). All animal-related procedures were approved by the Animal Experiment Ethics Committee of China Jiliang University (Approval No. 2021-005).

Genomic DNA was extracted from commercial specimens using the TakaRa MiniBEST Universal Genomic DNA Extraction Kit (Takara Bio, China) according to the manufacturer's instructions. Approximately 25 mg aliquots underwent manufacturer-specified pretreatment, followed by genomic DNA isolation according to the instructions. Extracted DNA was quantified via NanoDrop 2000 spectrophotometry (Thermo Fisher Scientific) and assessed for integrity through 1.5% agarose gel electrophoresis with GelRed staining.

2.2 Sequencing Analysis of Two *PRNP* Polymorphic Loci

Sequencing and validation analysis of the 12 bp and 23 bp indel polymorphisms was performed using primer pairs reported by Imran et al<sup>50</sup>, with the bovine *PRNP* gene sequence (GenBank accession No AJ298878.1) as the reference template. The polymorphic sequences were defined as 5'-GGGGGCCGCGGC-3' (12 bp) and 5'-TCTCAGATGTCTTCCAACAGCA-3' (23 bp).

All primers were synthesized by Hangzhou Tsingke Biotechnology Co. (China), with sequences detailed in Table 1.

**Table 1** Bovine *PRNP* Gene PCR Sequencing Primers


Polymorphic Locus	Primer	Primer Sequence (5'→3')
12bp indel	12indel F	GTGCTCGTTGGTTTTGC
	12indel R	TCCTACACACCCACATA
23bp indel	23indel F	AGCCAGGTAAGAAGCTCATC
	23indel R	CATGAATTGTAGGCCAA

PCR amplification targeting the 12 bp and 23 bp indel fragments in the bovine *PRNP* gene was performed separately using two independent primer sets under identical reaction conditions. The 20 µL reaction system followed the same PCR profile: 95°C for 5 min; 35 cycles of 94°C for 30 s, 60°C for 30 s, and 72°C for 45 s; 72°C for 10 min; and storage at 4°C. Amplification products were electrophoresed on 1.5% agarose gels, and fragments matching predicted sizes were purified and transferred to Hangzhou Tsingke Biotechnology (China Hangzhou) for bidirectional Sanger sequencing.

### 2.3 Tetra-ARMS PCR Primer Design

Tetra-ARMS PCR primers targeting the 12 bp and 23 bp indel polymorphic loci were designed based on the bovine *PRNP* gene reference sequence (GenBank accession No AJ298878.1) and sequencing data described in section 2.2, following primer designed principles<sup>39, 45, 47</sup> with the expected amplicon sizes constrained to 150-600 bp for clear electrophoretic resolution. The 12 bp inner primer (12-IF2) has 5-nucleotide complementarity at the 3'-terminus to the insertion sequence; and the 23 bp inner primer (23-IFA4) has 22-nucleotide complementarity at the 3'-terminus to the insertion sequence. To enhance the PCR specificity, an additional T-G weak mismatch was introduced at nucleotide position 5 (from the 5'-terminus) in the upstream inner primer 23-IFA4 for the 23 bp polymorphic locus, and a T-G mismatch at nucleotide position 3 (from the 3'-terminus) in the downstream inner primer 23-AR2. The primer design strategy is illustrated in Figure 1, with sequences provided in Table 2. All primers were synthesized by Hangzhou Tsingke Biotechnology Co., Ltd. (China), and diluted to 10  $\mu$ M, stored at 4°C for future use.

8



**Fig. 1** Schematic of Tetra-ARMS PCR primer design and expected electrophoretic results. (a) 12 bp polymorphic locus; (b) 23 bp polymorphic locus. Colour-coded arrows denote primers: for the 12 bp locus, outer primers (black), insertion-specific inner primer (red), deletion-specific inner primer (blue); for the 23 bp locus, outer primers (purple), insertion-specific inner primer (orange-red), deletion-specific inner primer (green). Lowercase bases indicate complementarity to insertion sequences; underlined bases represent engineered mismatches. Genotype abbreviations: Del genotypes (homozygous deletion), Hetero genotypes (heterozygous insertion/deletion), Ins genotypes (homozygous insertion).

**Table 2** Tetra-ARMS PCR Primer Sequences for Bovine *PRNP* indel Genotyping

DOI: 10.1039/D5AY02047F

Polymo Locus	Primer	Primer Sequence (5'→3')	Fragment length (bp)
	12-PF3	ACCTTGACCGTGAGTAGGGCTGGG	
12bp indel	12-IF2(I)	ACTCGGAATGTGGCggggg	472(I)
	12-Rin(D)	GGGGGACCAGCCAGCCCA	153(D)
	12-LR1	CGCCAGGTGGCCCATGATT	598/610
	23-PF1	GCAATGCAGCTCCATGTGTTACTGA	
23bp indel	23-IFA4(I)	ACGT <sup>T</sup> AAatctcagatgtttccaaacagc	193(I)
	23-AR2(D)	ACTCTGCCCATGACGCTCTGAGG <sup>T</sup> TT	259(D)
	23-PR3	CGTGAGGGTTGAGGAAACGAAATGA	
		C	422/445

In the Tetra-ARMS PCR primer system: In primer nomenclature "I" denotes the upstream inner primer for the insertion sequence, and "D" denotes the downstream inner primer for the deletion sequence. Lowercase letters in "I" primers indicate bases complementary to the insertion sequence, while letters enclosed in boxes represent intentionally introduced mismatch bases.

### 2.4 Tetra-ARMS PCR Amplification

#### 2.4.1 Basic PCR System and Optimization

Based on previously reported ARMS-PCR references system and conditions<sup>39, 45, 47</sup>, the 20  $\mu$ L PCR reaction system was prepared containing 2.0  $\mu$ L 10 $\times$  PCR buffer, 1.6  $\mu$ L dNTP mixture (25 mM), 2.0  $\mu$ L  $MgCl_2$  (25 mM), 0.5  $\mu$ L each of upstream/downstream outer primers (10  $\mu$ M), 0.8  $\mu$ L each of upstream/downstream inner primers (10  $\mu$ M), 0.4  $\mu$ L Taq DNA polymerase (5 U/ $\mu$ L; Thermo Fisher Scientific), 3.0  $\mu$ L template DNA, and 8.4  $\mu$ L ddH<sub>2</sub>O.

The basic PCR program used was as follows: initial denaturation at 95°C for 8 min; 35 cycles of 94°C for 35 s, annealing at (57°C, 60°C, 63°C, 66°C, 69°C and 72°C) for 40 s, 72°C for 1 min; followed by a final extension at 72°C for 10 min, and finally the PCR products were maintained at 4°C in the end. Optimal reaction conditions were determined through systematic optimization of annealing temperature (57-72°C gradient) and cycle number (30, 32, 35, 38 cycles). Subsequent optimizations included  $Mg^{2+}$  concentration (1.5, 2.0, 2.5, 3.0 mM) and primer concentration ratios (outer:inner from 5:1 to 1:5). PCR products were resolved by 2.0% agarose gel electrophoresis, with optimal reaction conditions selected based on product specificity and amplification efficiency.

## 1 ARTICLE

## 2

3 **2.4.2 Genotyping System for the 12 bp Polymorphic Locus**

4 Based on optimization results, the Tetra-ARMS PCR system for  
 5 the 12 bp polymorphic locus comprised a 20  $\mu$ L reaction  
 6 volume, which contained 2.0  $\mu$ L 10 $\times$  PCR buffer, 1.6  $\mu$ L dNTP  
 7 mixture (25 mM), 2.0  $\mu$ L MgCl<sub>2</sub> (25 mM), 0.5  $\mu$ L upstream  
 8 outer primer 12-PF3 (10  $\mu$ M), 0.8  $\mu$ L upstream inner primer 12-  
 9 IF2 (10  $\mu$ M), 0.4  $\mu$ L downstream inner primer 12-Rin (10  $\mu$ M),  
 10 0.8  $\mu$ L downstream outer primer 12-LR1 (10  $\mu$ M), 0.4  $\mu$ L Taq  
 11 DNA polymerase (5 U/ $\mu$ L; Thermo Fisher Scientific), 3.0  $\mu$ L  
 12 template DNA, and 8.5  $\mu$ L ddH<sub>2</sub>O. Thermal cycling was as  
 13 follows: initial denaturation at 95°C for 5 min; followed by 35  
 14 cycles at 94°C for 35 s, 69°C for 40 s, and 72°C for 1 min; the  
 15 extension at 72°C for 10 min, and finally the PCR products  
 16 were maintained at 4°C in the end.

17 **2.4.3 Genotyping System for the 23 bp Polymorphic Locus**

18 Based on optimization results, the Tetra-ARMS PCR system for  
 19 the 23 bp polymorphic locus comprised a 20  $\mu$ L reaction  
 20 volume, which contained 2.0  $\mu$ L 10 $\times$  PCR buffer, 1.6  $\mu$ L dNTP  
 21 mixture (25 mM), 2.0  $\mu$ L MgCl<sub>2</sub> (25 mM), 0.4  $\mu$ L upstream  
 22 outer primer 23-PF1 (10  $\mu$ M), 0.4  $\mu$ L upstream inner primer 23-  
 23 IFA4 (10  $\mu$ M), 0.3  $\mu$ L downstream inner primer 23-AR2 (10  $\mu$ M),  
 24 0.8  $\mu$ L downstream outer primer 23-PR3 (10  $\mu$ M), 0.4  $\mu$ L Taq  
 25 DNA polymerase (5 U/ $\mu$ L; Thermo Fisher Scientific), 3.0  $\mu$ L  
 26 template DNA, and 9.1  $\mu$ L ddH<sub>2</sub>O. Thermal cycling was  
 27 identical to the 12 bp system.

28 **2.4.4 Single-Tube Multiplex ARMS-PCR System**

29 A single-tube multiplex PCR system was preliminarily  
 30 established to explore the feasibility of simultaneous detection.  
 31 This system combines the primer sets from the two  
 32 independently optimized single-locus assays under their  
 33 consistent PCR conditions. The final 20  $\mu$ L reaction mixture  
 34 contained: 2.0  $\mu$ L 10 $\times$  PCR buffer, 1.6  $\mu$ L dNTP mixture (25 mM),  
 35 2.0  $\mu$ L of MgCl<sub>2</sub> (25 mM), 0.4  $\mu$ L upstream outer primer 12-PF3  
 36 (10  $\mu$ M), 2.2  $\mu$ L upstream inner primer 12-IF2 (10  $\mu$ M), 0.4  $\mu$ L  
 37 downstream inner primer 12-Rin (10  $\mu$ M), 1.0  $\mu$ L downstream  
 38 outer primer 12-LR1 (10  $\mu$ M), 0.4  $\mu$ L upstream outer primer  
 39 23-PF1 (10  $\mu$ M), 0.8  $\mu$ L upstream inner primer 23-IFA4 (10  $\mu$ M),  
 40 0.8  $\mu$ L downstream inner primer 23-AR2 (10  $\mu$ M), 0.8  $\mu$ L  
 41 downstream outer primer 23-PR3 (10  $\mu$ M), 0.4  $\mu$ L Taq DNA  
 42 polymerase (5 U/ $\mu$ L; Thermo Fisher Scientific), 3.0  $\mu$ L template  
 43 DNA, and 4.2  $\mu$ L ddH<sub>2</sub>O. Thermal cycling was identical to the  
 44 12 bp system.

45 **2.5 Limit of Detection (LOD) Assessment for Tetra-ARMS PCR**

46 DOI: 10.1039/D5AY02047F  
 47 To further explore the detection limit of ARMS-PCR, the  
 48 optimized detection system was used to assess it for different  
 49 genotypes using continuous gradient dilution of DNA. Genomic  
 50 DNA samples from individuals with three genotypes (Ins, Del,  
 51 Hetero) for both the 12 bp and 23 bp loci were selected (two  
 52 samples per genotype) as the template. DNA samples of  
 53 identical genotypes were mixed and subjected to 10-fold serial  
 54 dilution for detection limit assay.

55 **2.6 Genotyping of Commercial Cattle-Derived Products**

56 The *PRNP* genotypes of 62 commercial cattle-derived products  
 57 (raw milk, milk powder, beef and cheese) were determined  
 58 using an optimized single-locus Tetra-ARMS PCR system for  
 59 both the 12 bp and 23 bp polymorphic sites. Concurrently,  
 60 three samples per genotype were randomly selected for  
 61 bidirectional sequencing verification according to the method  
 62 in Section 2.2.

63 Based on ARMS-PCR electrophoretic profiles, allele and  
 64 genotype frequencies for both loci in the bovine *PRNP* gene  
 65 were calculated.

66 **3 Results and Analysis**67 **3.1 DNA Extraction and Quality**

68 The detection for concentration and OD value of 62 extracted  
 69 DNA samples revealed that the DNA concentration for meat  
 70 samples was  $46.2 \pm 9.55$  ng/ $\mu$ L, OD<sub>260/280</sub> ratio was  $1.93 \pm 0.07$ ;  
 71 for raw milk samples was  $2.69 \pm 1.09$  ng/ $\mu$ L and OD<sub>260/280</sub> was  
 72  $1.66 \pm 0.21$ ; for milk powder samples was  $6.93 \pm 2.65$  ng/ $\mu$ L  
 73 and OD<sub>260/280</sub> was  $1.74 \pm 0.23$ . PCR products showed that all  
 74 the DNA samples could amplify the specific *PRNP* gene  
 75 containing the 12 bp and 23 bp polymorphic sites,  
 76 demonstrating that the DNA concentrations and purity meet  
 77 the PCR analysis requirements.


78 **3.2 Sequencing-Based Genotyping for the two *PRNP* Polymorphic  
 79 Loci**

80 Electrophoretic analysis of *PRNP* amplicons indicated the  
 81 obtained fragment sizes was 119/131 bp for 12 bp locus and  
 82 245/268 bp for 23 bp locus and showed in Figure 2, consistent  
 83 with expected sizes. However, the close proximity of fragment  
 84 sizes impeded definitive genotyping by electrophoresis.  
 85 Sequence alignment using EditSeq and MegAlign software  
 86 confirmed the presence of three genotypes per locus,


## Journal Name

## ARTICLE

including homozygous deletion (Del genotypes), homozygous insertion (Ins genotypes), and insertion-deletion heterozygote (Hetero genotypes), as shown in Figure 3.



**Fig. 2** Electrophoretic analysis of *PRNP* gene 12 bp and 23 bp polymorphic loci. Lane M represents DNA Marker C (100–1200 bp). (a) PCR products amplified with 12 indel FR primers; (b) PCR products amplified with 23 indel FR primers. Lane 1 represents negative control (NTC), Lanes 2–3 represent Del genotypes (−/−), Lanes 4–5 represent Hetero genotypes (+/−), Lanes 6–7 represent Ins genotypes (+/+)




**Fig. 3** Sanger Sequencing Chromatograms of *PRNP* gene 12 bp and 23 bp polymorphisms. (a) 12 bp indel polymorphism; (b) 23 bp indel polymorphism. Del genotypes (−/−), Hetero genotypes (+/−), Ins genotypes (+/+).

### 3.3 ARMS-PCR Genotyping Systems

#### 3.3.1 Single-Locus Detection Systems

Using the known *PRNP* genotype individuals (Ins, Del, Hetero) as standard referenced DNA templates for both loci, tetra-primer ARMS-PCR amplifications were carried out and the results showed distinct electrophoretic profiles in Figure 4. For the 12 bp polymorphic locus, all the DNA samples from three genotypes produced positive control products, the individuals with Del genotypes obtained a control product of 598 bp, the individuals with Ins genotypes or Hetero genotypes obtained a control product of 610 bp. Correspondingly, the individuals with Ins genotypes obtained products of a control 610 bp fragment, and a specific 472 bp fragment. The individuals with Del genotypes obtained products of a control 598 bp and a specific 153 bp. The individuals with Hetero genotypes

obtained products of a control 610 bp fragment, and also 472 bp and 153 bp specific fragments. For the 23 bp polymorphic locus, the positive control products were 422 bp and 445 bp, corresponding with Del genotypes and Ins genotypes or Hetero genotypes, respectively. Furthermore, the individuals with Ins genotypes obtained 445 bp and 193 bp fragments. The individuals with Hetero genotypes obtained 445 bp, 259 bp and 193 bp fragments. The individuals with Del genotypes only obtained 422 bp (control) and 259 bp PCR products. These fragment patterns clearly distinguished all genotypes at both loci, demonstrating the high efficiency and accuracy of the ARMS-PCR system.




**Fig. 4** ARMS-PCR Electrophoresis results for 12 bp (a) and 23 bp (b) Polymorphisms. Lane M represents DNA Marker C (100–1200 bp); Lane 1 represents negative control (NTC); Lanes 2–3 represent Ins genotypes (+/+); Lanes 4–5 represent Del genotypes (−/−); Lanes 6–7 represent Hetero genotypes (+/−).

#### 3.3.2 Preliminary Exploration of a Multiplex Detection System

Based on the optimized conditions for each single-locus assay, a preliminary multiplex PCR system containing both primer sets was configured to explore the feasibility of simultaneous detecting system. Following the conditions, this system simultaneously detected both 12 bp and 23 bp indel polymorphisms in the bovine *PRNP* gene. All genotypes were successfully verified using the DNA samples. The reactions yielded the expected positive control bands (598/610 bp for the 12 bp locus ; 422/445 bp for the 23 bp locus) and genotype-specific fragments. No non-specific amplification was observed. Electrophoretic results allowed clear genotype interpretation in Figure 5, with PCR product combinations detailed in Table 3. It should be noted that this multiplex system represents a preliminary proof of concept, established to validate its fundamental feasibility. Its stability, general applicability, and performance with larger sample sets require further systematic optimization and validation.

## ARTICLE



**Fig. 5** Multiplex ARMS-PCR for simultaneous genotyping of 12 bp and 23 bp indel polymorphisms. Lane M represents DNA Marker C (100–1200 bp); Lanes 1–9 represent Genotyped samples (annotated above figure); Lane 10 represents negative control (NTC).

**Table 3** Fragment Profile Matrix for Multiplex ARMS-PCR Genotyping


12 bp genotype	23 bp genotype	Fragment length (bp)	Total Bands
++	++	610, 472, 445, 193	4
++	+-	610, 472, 445, 259, 193	5
++	--	610, 472, 422, 259	4
+-	++	610, 472, 445, 193, 153	5
+-	+-	610, 472, 445, 259, 193, 153	6
+-	--	610, 472, 422, 259, 153	5
--	++	598, 445, 193, 153	4
--	+-	598, 445, 259, 193, 153	5
--	--	598, 422, 259, 153	4

Symbols '+' and '-' represent insertion and deletion at the gene locus, respectively.

### 3.4 Limit of Detection for ARMS-PCR

Using the verified DNA templates of three genotypes at the 12 bp and 23 bp polymorphic loci as the test samples, the detection limits of the individual single-locus tetra-ARMS PCR assays were assessed using 10-fold serial dilutions. Following PCR amplification with the two separate tetra-primer systems, agarose gel electrophoresis results in Figure 6 revealed that locus-specific LOD values were as follows: For the 12 bp locus, the minimum detectable concentration of genomic DNA template with Del genotypes was 4.53 ng/µL (0.6795 ng/µL in PCR system), for Hetero genotypes was 5.39 ng/µL (0.8085 ng/µL in PCR system), for Ins genotypes was 5.01 ng/µL (0.7515 ng/µL in PCR system). For the 23 bp locus: the

minimum concentration of DNA template with Del genotypes was 4.14 ng/µL (0.621 ng/µL in PCR system), for Hetero genotypes was 4.15 ng/µL (0.6225 ng/µL in PCR system), for Ins genotypes was 0.516 ng/µL (0.0774 ng/µL in PCR system). The overall detection limit ranged from 0.516 to 5.39 ng/µL (0.0774–0.8085 ng/µL in PCR system). To contextualize the relative sensitivity level of the developed assay, its detection limits were compared with those reported for other applications of the Tetra-ARMS PCR technique in the literature, as summarized in Table 4. The 23 bp Ins genotypes showed 10-fold higher sensitivity, potentially attributable to the lower GC content in insertion-specific primers enhancing amplification efficiency.



**Fig. 6** LOD Analysis of Tetra-ARMS PCR. (a) 12 bp locus (left to right: Del genotypes−/−, Hetero genotypes+−/−, Ins genotypes++); (b) 23 bp locus (left to right: Del genotypes−/−, Hetero genotypes+−/−, Ins genotypes+−/−). Lane M represents DNA Marker C (100–1200 bp); Lane 1 represents No-template control; Lanes 2–6 represent 10 fold serial dilutions ( $10^0$  to  $10^{-4}$ ).

**Table 4** Comparison of the limit of detection (LOD) of Tetra-ARMS PCR methods across different studies

Method	Target Locus	LOD	Reference
Tetra-ARMS PCR	Bovine PRNP gene 12/23 bp indel	0.516–5.39 ng/µL	This work
Multi ARMS-PCR	Apolipoprotein E genotyping	10ng	Lian et al., 2016 <sup>51</sup>
Tetra-ARMS PCR	SARS-CoV-2	78.91 copies/µL	Wang et al., 2022 <sup>52</sup>
TaqMan ARMS-PCR	mitochondrial DNA (mtDNA) 1555A>G	0.1 ng/µL	Tan et al., 2024 <sup>53</sup>


### 3.5 Commercial product Genotyping

The two aforementioned primer sets were used to amplify the 62 commercially available bovine-derived products. The results

## ARTICLE

## Journal Name

for the 12 bp locus were 18 Del, 13 Ins, and 31 Hetero; for the 23 bp locus, they were 12 Del, 9 Ins, and 41 Hetero.. Among these, the identification results of 24 samples are shown in Figure 7. The electrophoresis detection results were completely consistent with DNA sequencing, demonstrating that this study provides an accurate and intuitive detection method for genotyping the bovine *PRNP* gene. Based on electrophoretic genotyping results, allele and genotype frequencies were calculated for the 12 bp and 23 bp loci in the bovine *PRNP* gene. For the 12 bp locus, 21.9% of samples belonged to Ins genotype, 49.2% belonged to Hetero genotype and 28.9% belonged to Del genotype. For the 23 bp locus, 20.9% belonged to Ins genotype, 51.2% belonged to Hetero genotype, and 27.9% belonged to Del genotype. Polymorphism differences between loci are detailed in Table 4.



**Fig. 7** Genotyping Results of Commercial Samples. (a) 12 bp indel polymorphism. Lane M represents DNA Marker C (100–1200 bp); Lanes 2,5,6,8,10,12,14,16,19,21,23,24 represent Del genotypes (−/−); Lanes 1,4,9,15,17,18 represent Hetero genotypes (+/−); Lanes 3,7,11,13,20,22 represent Ins genotypes (+/+). (b) 23-bp indel polymorphism. Lanes 10,11,12,17,18,19,21 represent Del genotypes (−/−); Lanes 7,8,9,14,15,16,20,24 represent Hetero genotypes (+/−); Lanes 1,2,3,4,5,6,13,22,23 represent Ins genotypes (+/+).

**Table 5** Allele and genotype frequencies of insertion/deletion polymorphisms in the bovine *PRNP* gene

Locus	n	Allele frequency		Genotype frequency		
		Insertion	Deletion	+/-	+/-	-/-
		Allele	Allele			
12 bp+/-	62	0.460	0.540	0.219	0.492	0.289
23 bp+/-		0.465	0.535	0.209	0.512	0.279

## 4 Discussions

View Article Online

DOI: 10.1039/D5AY02047F

Since the completion of bovine *PRNP* gene sequencing in 2001, extensive research has characterized its genetic polymorphisms<sup>23</sup>. Among 60 polymorphic sites identified in the gene sequence, the 23 bp indel polymorphism in the promoter region showed significant association with BSE susceptibility, with deletion homozygotes and heterozygotes exhibiting higher disease risk<sup>2</sup>. Subsequent studies revealed the 12 bp indel polymorphism in the intron region similarly correlates with BSE resistance/susceptibility. Individuals carrying both 23 bp and 12 bp insertions demonstrate the strongest resistance to BSE, while double-deletion homozygotes show maximal susceptibility<sup>54</sup>. These polymorphic sites regulate prion protein (PrP) expression levels and conformational stability, directly impacting pathological accumulation and transmission efficiency of PrP<sup>Sc</sup><sup>6, 21, 55, 56</sup>. Molecular analyses indicated that 12 bp deletion abolishes transcription factor SP1 binding sites, reducing transcriptional efficiency, while 23 bp deletion interferes with 58 kDa repressor protein (RP58) binding, altering chromatin conformation. Both mechanisms converge on *PRNP* gene regulatory networks, ultimately affecting prion protein metabolic homeostasis<sup>57-59</sup>. Additionally, the *PRNP* gene contains other polymorphic sites such as E211K that influence prion protein structure<sup>60, 61</sup>. Nevertheless, the 12 bp and 23 bp polymorphic sites remained central to disease-resistant breeding applications and BSE safety assessments in cattle<sup>28, 62-64</sup>.

The critical impact and significance of *PRNP* gene polymorphisms in animal breeding has driven extensive development of detection methodologies, including Sanger sequencing<sup>22, 29-34</sup>, PCR-RFLP analysis<sup>35</sup>, quantitative PCR (qPCR)<sup>36</sup>, next-generation sequencing (NGS)<sup>37</sup>, and microarray genotyping<sup>38</sup>. However, these platforms and developed methods are constrained by expensive instrumentation, high reagent costs, operational complexity, and prolonged processing times. In contrast, ARMS-PCR provides a simple, cost-effective solution for detecting of single nucleotide polymorphisms (SNPs) and small indels. Currently, this

## 1 ARTICLE

2 technology is used in medical diagnostics for precision  
 3 genotyping of breast cancer susceptibility alleles<sup>65</sup>, genetic risk  
 4 assessment for mosquito-borne diseases<sup>66</sup>, and polygenic  
 5 analysis of colorectal cancer<sup>67</sup>. The applications in agricultural  
 6 field include screening for bovine complex vertebral  
 7 malformation (CVM) susceptibility<sup>68</sup> and authentication of  
 8 Thai bird's nest products<sup>69</sup>. Within livestock genetics, rapid  
 9 genotyping of leptin receptor mutations in rats<sup>70</sup> and ASB-3  
 10 gene polymorphisms affecting bovine growth traits<sup>71</sup>.  
 11 Extensive applications demonstrated that optimized ARMS-  
 12 PCR with refined primer design and reaction conditions  
 13 delivered visual electrophoretic results within 2-3 hours. With  
 14 minimal costs and scalability for large-scale screening, this  
 15 method provides an efficient and economical solution for  
 16 genetic analysis.

17 This study established two streamlined, independent  
 18 genotyping assays for bovine *PRNP* 12 bp and 23 bp indel  
 19 polymorphisms based on Tetra-ARMS PCR technology. The  
 20 developed single-locus assays can efficiently identify *PRNP* 12  
 21 bp and 23 bp indel genotypes of cattle and cattle-derived  
 22 products with simplicity, low cost, and high efficiency. ARMS-  
 23 PCR amplifies target sequences only with perfect 3'-end  
 24 complementarity to template DNA, blocking amplification  
 25 otherwise. Incorporating outer primers as positive controls  
 26 creates a tetra-primer system<sup>39, 45</sup>. This design enhances  
 27 accuracy by reducing false negatives and ambiguous results in  
 28 practical applications.

29 This study designed an optimized Tetra-ARMS PCR system  
 30 targeting for 12 bp and 23 bp indel polymorphisms in the  
 31 bovine *PRNP* gene, which provided a better method for *PRNP*  
 32 genotyping technology. It is worth mentioning that, the Tetra  
 33 ARMS PCR primers designed in this study are different from  
 34 other SNP genotyping primers, all the primers were designed  
 35 only for inserting genotype sequences with multiple bases  
 36 complementary to the insertion sequence at the 3' end of the  
 37 inner primer which had higher accuracy and sensitivity than  
 38 other common Tetra ARMS PCR single base mismatches.  
 39 Critically, inner primer sequences fully featured extended 3' -  
 40 terminal complementarity to insertion sequences, specifically,

41 5 nucleotides in 12-IF2 and 22 nucleotides in 23-IFA4, were  
 42 complete pairing the 12 bp and 23 bp insertion sequences,  
 43 which ensure the specificity of PCR amplification. This design  
 44 achieved detection limits as low as 0.516 ng/µL genomic DNA,  
 45 is comparable to that of other established Tetra-ARMS PCR  
 46 applications, includes the assay reported for apolipoprotein E  
 47 genotyping<sup>51</sup>. Moreover, the specificity was enhanced through  
 48 introduced a T-G mismatch at position 5 (from 5' -terminus)  
 49 in primer 23-IFA4 and position 3 (from 3' -terminus) in primer  
 50 23-AR2. These strategically positioned weak suppress non-  
 51 specific amplification while improving allelic discrimination<sup>39,</sup>  
 52 <sup>72</sup>, aligning with established principles for enhancing ARMS-  
 53 PCR accuracy.

54 The concentration ratio of primers in the Tetra ARMS PCR  
 55 reaction system is also a key factor affecting specificity and  
 56 sensitivity. Due to the presence of multiple mismatch sites in  
 57 the inner specific primer, the amplification efficiency of the  
 58 outer primers is higher than that of the inner primer, as they  
 59 are completely matched. Therefore, adjusting primer  
 60 concentration ratios were adopted to counterbalance  
 61 amplification efficiency disparities between fully matched  
 62 outer primers and mismatch-containing inner primers<sup>73</sup>.  
 63 Specifically, by increasing inner primer concentrations, this  
 64 study resolved amplification imbalances.

65 Furthermore, the annealing temperature is another  
 66 critical factor influencing PCR amplification, and its effect in  
 67 the Tetra-ARMS PCR system indicates that as the annealing  
 68 temperature gradually increases, the specificity of the two sets  
 69 of primers will also be correspondingly enhanced. This study  
 70 has demonstrated this phenomenon that annealing  
 71 temperature optimization addressed the problem of low PCR  
 72 efficiency due to high GC content (73%) in the 12 bp insertion  
 73 sequence (GGGGGCCGCGGC). At 69°C, exceeding conventional  
 74 PCR Tm values, the specific target amplification was achieved  
 75 while eliminating non-specific products.

76 The principal value of the assay developed herein is its  
 77 potential to significantly reduce the economic and temporal  
 78 barriers associated with screening for these important *PRNP*  
 79 indels. Compared to the gold-standard Sanger sequencing,  
 80 which is accurate but costly and slower for batch processing,

1 **Journal Name**2 **ARTICLE**

3 our method requires only a conventional PCR thermocycler  
 4 and standard gel electrophoresis apparatus, instruments  
 5 accessible in most molecular biology laboratories. Reagent  
 6 costs are minimal, and the workflow from DNA to genotype  
 7 can be completed within approximately 3 hours, enabling high-  
 8 throughput analysis. This makes it a viable and attractive  
 9 option for large-scale screening within breeding programs  
 10 aimed at increasing BSE resistance in cattle populations. By  
 11 facilitating the cost-effective identification of resistant (Ins/Ins)  
 12 individuals, the method directly supports DNA marker-assisted  
 13 selection. Additionally, its successful application to commercial  
 14 products (milk, beef, cheese) demonstrates utility in the  
 15 genetic traceability and risk assessment of animal-derived  
 16 foods, contributing to safety monitoring in the food chain.

17 Nevertheless, this study has certain limitations. First, the  
 18 developed multiplex detection system requires further  
 19 systematic optimization to improve its stability and  
 20 reproducibility across different laboratory conditions. Second,  
 21 although validated using commercial processed products (e.g.,  
 22 milk powder, cheese), the performance of the method on  
 23 highly degraded or low-quality DNA<sup>74</sup>, or with extreme sample  
 24 matrices containing complex inhibitory substances<sup>75</sup>, remains  
 25 to be specifically evaluated in future work. Finally, as a  
 26 technique based on end-specific amplification, its accuracy  
 27 depends on precise primer design and stringent PCR condition  
 28 control, which requires careful attention to experimental  
 29 technique.

30 Additionally, the ARMS-PCR framework demonstrates  
 31 potential prospects for integration with advanced platforms.  
 32 Combination it with lateral flow chromatography enabled  
 33 SARS-CoV-2 detection limit to 1.90 copies/µL<sup>61</sup>, coupled with  
 34 digital PCR achieved detection limit to 0.308 copies/µL for  
 35 epidermal growth factor receptor mutations<sup>76</sup>. Such  
 36 integrations highlight its promise for future ultra-sensitive  
 37 diagnostics.

38 In summary, the Tetra-ARMS PCR method established in  
 39 this study offers significant advantages of low cost and high  
 40 efficiency, over existing techniques for analysing 12 bp and 23  
 41 bp indel polymorphisms in bovine *PRNP* gene. It provides a  
 42 viable option for large-scale screening of disease-resistant  
 43 animal individuals. Furthermore, disease resistance breeding

44 represents an important safeguard for animal husbandry  
 45 safety and public health, holding significant scientific value and  
 46 societal value.

47 **5 Conclusions**

48 This study successfully developed and validated two  
 49 independent tetra-ARMS PCR assays for the efficient  
 50 genotyping of 12 bp and 23 bp indel polymorphisms in the  
 51 bovine *PRNP* gene. Furthermore, a preliminary multiplex  
 52 configuration was demonstrated, outlining a clear pathway for  
 53 future development toward a single-tube, high-throughput  
 54 screening tool. The established single-locus methods offer a  
 55 cost-effective, high-throughput screening, addressing  
 56 limitations of existing methods. This approach significantly  
 57 advances disease-resistant cattle DNA marker assisted  
 58 breeding and safety assessment of animal-derived food  
 59 products.

60 **Author contributions**

61 Ye Xu: conceptualization, methodology, investigation, writing –  
 62 original draft. Siyu Yang: conceptualization, methodology. Siling  
 63 Ding and Ting Xu: investigation. Jian Ge: investigation, formal  
 64 analysis. Weiming Xiao: resources. Like Zhu: funding acquisition,  
 65 project administration. Feng Guan: supervision, writing – review &  
 66 editing.

67 **Conflicts of interest**

68 There are no conflicts to declare.

69 **Data availability**

70 The raw sequence data reported in this paper have been  
 71 deposited in the Genome Sequence Archive (Genomics,  
 72 Proteomics & Bioinformatics 2025) in National Ge-nomics Data  
 73 Centre (Nucleic Acids Res 2025), China National Centre for  
 74 Bioinformation / Beijing Institute of Genomics, Chinese  
 75 Academy of Sciences (GSA: accession number CRA030580) that  
 76 are publicly accessible at <https://ngdc.cncb.ac.cn/gsa>. All data  
 77 generated or analysed in this study are available.

78 **Acknowledgements**

79 Not applicable.

80 **Ethical approval**

## ARTICLE

## Journal Name

The blood samples used for genomic DNA isolation were originally collected as part of routine herd health monitoring programs by the collaborating farms and research institutes. All animal-related procedures in this study were conducted in strict compliance with the national regulations and guidelines of the People's Republic of China, including the "Regulations for the Administration of Affairs Concerning Experimental Animals" and the "Guideline on the Humane Treatment of Laboratory Animals". The protocol for the retrospective genetic analysis of these pre-existing DNA samples was reviewed and formally approved by the Animal Experiment Ethics Committee of China Jiliang University (Approval No. 2021-005). This research did not involve human participants.

**Funding**

This work was supported by grants from the National Natural Science Foundation of China (31672394), Zhejiang Science and Technology Major Program on Agricultural New Variety Breeding (2021C02068-6), Zhejiang Province Agricultural Major Technology Collaborative Promotion Plan (2023ZDXT16-3), the Project for Zhejiang Province Basic Public Welfare Research Program (LTGN24C050001, 2026C02A3025), China Agriculture Research System (CARS-39-07), Young Science and Technology Top Talent Program of Tianshan Talent Training Program in Xinjiang Province (2022TSYCCX0124), Xinjiang Agriculture Research System (XJARS-09-26), as well as Project of Corps Science and Technology in Key Areas (2024AB017).

**Notes and references**

1. S. B. Prusiner, *Science*, 1982, **216**, 136-144.
2. P. Sander, H. Hamann, I. Pfeiffer, W. Wemheuer, B. Brenig, M. H. Groschup, U. Ziegler, O. Distl and T. Leeb, *Neurogenetics*, 2004, **5**, 19-25.
3. U. Rasheed, M. Khalid, A. Noor, U. Saeed, R. Uppal and S. Zafar, *Prion*, 2024, **18**, 1-7.
4. M. C. Jurcau, A. Jurcau, R. G. Diaconu, V. O. Hoga and V. S. Nunkoo, *Neurol Int*, 2024, **16**, 1039-1065.
5. S. Liu, S. E. Heumüller, A. Hossinger, S. A. Müller, O. Buravlova, S. F. Lichtenhaler, P. Denner and I. M. Vorberg, *Nat Commun*, 2023, **14**, 5034.
6. L. Orge, C. Lima, C. Machado, P. Tavares, P. Mendonça, P. Carvalho, J. Silva, M. L. Pinto, E. Bastos, J. C. Pereira, N. Gonçalves-Anjo, A. Gama, A. Esteves, A. Alves, A. C. Matos, F. Seixas, F. Silva, I. Pires, L. Figueira, M. Vieira-Pinto, R. Sargo and M. D. A. Pires, *Biomolecules*, 2021, **11**, 1-29.
7. S. Gilch and H. M. Schatzl, *Cell Tissue Res*, 2023, **392**, 1-5.
8. S. A. Madsen-Bouterse, M. A. Highland, R. P. Dassanayake, D. Zhuang and D. A. Schneider, *PLoS One*, 2018, **13**, e0204281.
9. C. Ligios, M. G. Cancedda, A. Carta, C. Santucciu, C. Maestrale, F. Demontis, M. Saba, C. Patta, J. C. DeMartini, A. Aguzzi and C. J. Sigurdson, *J Virol*, 2025, **99**, e0073125.
10. T. Onodera and A. Sakudo, in *Prions: Current Progress in Advanced Research (Second Edition)*, 2019, DOI: 10.21775/9781910190951.01.
11. M. A. Tranulis and M. Tryland, *Foods*, 2023, **12**, View Article Online
12. A. M. Zaharioiu, C. Șandru, E. I. Ionete, F. Marin, E. Ionete, A. Soare, M. Constantinescu, F. Bucura and V. C. Niculescu, *Materials (Basel)*, 2022, **15**.
13. C. M. Carlson, S. Thomas, M. W. Keating, P. Soto, N. M. Gibbs, H. Chang, J. K. Wiepz, A. G. Austin, J. R. Schneider, R. Morales, C. J. Johnson and J. A. Pedersen, *iScience*, 2023, **26**, 108428.
14. A. Sakudo, *Curr Issues Mol Biol*, 2020, **36**, 13-22.
15. R. A. Williamson, D. Peretz, N. Smorodinsky, R. Bastidas, H. Serban, I. Mehlhorn, S. J. DeArmond, S. B. Prusiner and D. R. Burton, *Proc Natl Acad Sci U S A*, 1996, **93**, 7279-7282.
16. K. J. Park, H. C. Park, Y. R. Lee, G. Mitchell, Y. P. Choi and H. J. Sohn, *mSphere*, 2025, **10**, e0086624.
17. T. A. Nichols, B. Pulford, A. C. Wyckoff, C. Meyerett, B. Michel, K. Gertig, E. A. Hoover, J. E. Jewell, G. C. Telling and M. D. Zabel, *Prion*, 2014, **3**, 171-183.
18. E. Y. Teferedegn, H. Can, S. Erkunt Alak and C. Ün, *Animal biotechnology*, 2023, **34**, 1931-1936.
19. X. He, S. Memon, D. Yue, J. Zhu, Y. Lu, X. Liu, H. Xiong, G. Li, W. Deng and D. Xi, *Animals : an open access journal from MDPI*, 2023, **13**.
20. A. Gurgul, M. P. Polak, M. Larska and E. Slota, *Journal of applied genetics*, 2012, **53**, 337-342.
21. E. D. Cassmann, A. J. Frese, K. A. Becker and J. J. Greenlee, *Front Vet Sci*, 2023, **10**, 1301998.
22. A. C. Adeola, S. F. Bello, A. M. Abdussamad, R. A. M. Adedokun, S. C. Olaogun, N. Abdullahi, A. I. Mark, A. B. Onoja, O. J. Sanke, G. F. Mangbon, J. Ibrahim, P. M. Dawuda, A. E. Salako, S. Kdidi and M. H. Yahyaoui, *BMC genomics*, 2024, **25**, 177.
23. D. Hills, S. Comincini, J. Schlaepfer, G. Dolf, L. Ferretti and J. L. Williams, *Anim Genet*, 2001, **32**, 231-232.
24. S. Mead, S. Lloyd and J. Collinge, *Annual review of genetics*, 2019, **53**, 117-147.
25. I. S. Roh, Y. C. Kim, H. J. Kim, S. Y. Won, M. J. Jeong, J. Y. Hwang, H. E. Kang, H. J. Sohn and B. H. Jeong, *Vet Rec*, 2022, **190**, e940.
26. K. Moazami-Goudarzi, O. Andréoletti, J. L. Villette and V. Béringue, *Vet Res*, 2021, **52**, 128.
27. Y. R. Lee, Y. C. Kim, S. Y. Won, M. J. Jeong, K. J. Park, H. C. Park, I. S. Roh, H. E. Kang, H. J. Sohn and B. H. Jeong, *Vet Res*, 2023, **54**, 48.
28. J. Ren, T. Hai, Y. Chen, K. Sun, Z. Han, J. Wang, C. Li, Q. Wang, L. Wang, H. Zhu, D. Yu, W. Li and S. Zhao, *Sci China Life Sci*, 2024, **67**, 555-564.
29. M. L. Clawson, M. P. Heaton, J. W. Keele, T. P. Smith, G. P. Harhay, J. A. Richt and W. W. Laegreid, *BMC Res Notes*, 2008, **1**, 32.
30. S. Y. Won, Y. C. Kim, K. Do and B. H. Jeong, *Animals : an open access journal from MDPI*, 2021, **11**.
31. X. He, S. Memon, D. Yue, J. Zhu, Y. Lu, X. Liu, H. Xiong, G. Li, W. Deng and D. Xi, *Animal biotechnology*, 2023, **34**, 2433-2440.
32. J. C. Pereira, N. Gonçalves-Anjo, L. Orge, M. A. Pires, S. Rocha, L. Figueira, A. C. Matos, J. Silva, P. Mendonça, P. Carvalho, P. Tavares, C. Lima, A. Alves, A. Esteves, M. L. Pinto, I. Pires, A. Gama, R. Sargo, F. Silva, F. Seixas, M. Vieira-Pinto and E. Bastos, *Prion*, 2023, **17**, 75-81.
33. A. C. Adeola, S. F. Bello, A. M. Abdussamad, A. I. Mark, O. J. Sanke, A. B. Onoja, L. M. Nneji, N. Abdullahi, S. C.

## ARTICLE

## Journal Name

- Olaogun, L. D. Rogo, G. F. Mangbon, S. L. Pedro, M. P. Hiinan, M. M. Mukhtar, J. Ibrahim, H. Saidu, P. M. Dawuda, R. K. Bala, H. L. Abdullahi, A. E. Salako, S. Kdidi, M. H. Yahyaoui and T. T. Yin, *Gene*, 2023, **855**, 147121.
34. M. R. Gurau, E. Negru, T. Ionescu, A. A. Udriste, C. P. Cornea and S. Baraitareanu, *Genes (Basel)*, 2022, **13**.
35. A. Psifidi, Z. Basdagianni, C. I. Dovas, G. Arsenos, E. Sinapis, M. Papanastassopoulou and G. Banos, *Anim Genet*, 2011, **42**, 406-414.
36. M. Van Poucke, J. Vandesompele, M. Mattheeuws, A. Van Zeveren and L. J. Peelman, *BMC Infectious Diseases*, 2005, **5**, 13.
37. V. V. Giau, E. Bagyinszky, Y. S. Yang, Y. C. Youn, S. S. A. An and S. Y. Kim, *Sci Rep*, 2019, **9**, 8368.
38. C. Ferrari, C. Punturiero, R. Milanesi, A. Delledonne, A. Bagnato and M. G. Strillacci, *Veterinary research*, 2024, **55**, 99.
39. S. Ye, S. Dhillon, X. Ke, A. R. Collins and I. N. Day, *Nucleic Acids Res*, 2001, **29**, E88-88.
40. A. Mukherjee and T. Chattopadhyay, *Methods in molecular biology (Clifton, N.J.)*, 2023, **2638**, 315-325.
41. S. A. Song, J. G. Shin and S. H. Oh, *Annals of clinical and laboratory science*, 2024, **54**, 519-524.
42. A. Khalil, H. N. Khan, M. Wasim, H. Ayesha and F. R. Awan, *Nucleosides, nucleotides & nucleic acids*, 2024, **43**, 517-529.
43. M. Hussain, H. N. Khan, S. Abbas, A. Ali, M. N. Aslam and F. R. Awan, *Nucleosides, nucleotides & nucleic acids*, 2023, DOI: 10.1080/15257770.2023.2181972, 1-16.
44. S. Torki, M. Nezhadali, M. Hedayati, H. Karimi, S. A. Razavi and L. Najd Hassan Bonab, *Nucleosides, nucleotides & nucleic acids*, 2024, DOI: 10.1080/15257770.2024.2354427, 1-12.
45. P. K. Dubey, S. Dubey, S. Singh, P. D. Bhat, S. Pogwizd and P. Krishnamurthy, *PLoS one*, 2024, **19**, e0293105.
46. L. Najd-Hassan-Bonab, M. Hedayati, S. A. Shahzadeh Fazeli and M. S. Daneshpour, *Heliyon*, 2023, **9**, e21102.
47. Y. Ke-Xin, C. Xiang, H. Qing-Qing, Y. Yi-An, W. Xiao-Ming, X. Ai-Chun, G. Jian and G. Feng, *Analytical sciences : the international journal of the Japan Society for Analytical Chemistry*, 2023, **39**, 1947-1956.
48. H. Yang, S. Yang, X. Xia, R. Deng, H. Gao and Y. Dong, *Journal of agricultural and food chemistry*, 2022, **70**, 8451-8457.
49. J. Chen, X. Xu, P. Dalhaimer and L. Zhao, *Animals : an open access journal from MDPI*, 2022, **12**.
50. M. Imran, S. Mahmood, M. E. Babar, R. Hussain, M. Z. Yousaf, N. B. Abid and K. P. Lone, *Gene*, 2012, **505**, 180-185.
51. T. Lian, W. Hui, X. Li, C. Zhang, J. Zhu, R. Li, Y. Wan and Y. Cui, *Molecular Medicine Reports*, 2016, **14**, 4153-4161.
52. Y. Wang, H. Chen, H. Wei, Z. Rong and S. Wang, *Lab on a Chip*, 2022, **22**, 1531-1541.
53. J. Tan, X. Zhang, X. Wei and M. Ding, *Current Issues in Molecular Biology*, 2024, **46**, 5454-5466.
54. K. Juling, H. Schwarzenbacher, J. L. Williams and R. Fries, *BMC Biology*, 2006, **4**, 33.
55. L. Orge, M. Lurdes Pinto, P. Cristovão, P. Mendonça, P. Carvalho, C. Lima, H. Santos, A. Alves, F. Seixas, I. Pires, A. Gama and M. Dos Anjos Pires, *J Vis Exp*, 2023, DOI: 10.3791/64560.
56. H. Zhao, S.-Q. Wang, L.-L. Qing, L.-L. Liu and Y.-P. Zhang, *Sci Bull*, 2016, **61**, 1-7. DOI: 10.1039/D5AY02047F
57. P. Sander, H. Hamann, C. Drögemüller, K. Kashkevich, K. Schiebel and T. Leeb, *Journal of Biological Chemistry*, 2005, **280**, 37408-37414.
58. C. L. Haigh, J. A. Wright and D. R. Brown, *J Mol Biol*, 2007, **368**, 915-927.
59. K. Kashkevich, A. Humeny, U. Ziegler, M. H. Groschup, P. Nicken, T. Leeb, C. Fischer, C.-M. Becker and K. Schiebel, *The FASEB Journal*, 2007, **21**, 1547-1555.
60. C. R. Troth, A. Burian, Q. Mauvisseau, M. Bulling, J. Nightingale, C. Mauvisseau and M. J. Sweet, *Sci Total Environ*, 2020, **748**, 141394.
61. E. M. Nicholson, B. W. Brunelle, J. A. Richt, M. E. Kehrli, Jr. and J. J. Greenlee, *PLoS One*, 2008, **3**, e2912.
62. A. Masone, C. Zucchelli, E. Caruso, G. Musco and R. Chiesa, *Neural regeneration research*, 2025, **20**, 1009-1014.
63. C. S. Han, S. Y. Won, S. H. Park and Y. C. Kim, *Animals : an open access journal from MDPI*, 2025, **15**.
64. R. Benavente, F. Brydon, F. Bravo-Risi, P. Soto, J. H. Reed, M. Lockwood, G. Telling, M. A. Barria and R. Morales, *Emerging infectious diseases*, 2025, **31**, 363-367.
65. W. E. Nough, E. F. El Azab, E. A. Oraby, S. M. Ahmed, M. A. El-Eshmawy, H. K. Badawy, E. I. A. Shaaban, N. S. El-Beltagy, H. A. Alrub, E. Wahsh, H. A. M. Elmarshad, A. M. Elsaied, A. E. T. M. Elhassan, E. Toraih, R. M. Elshazli, A. I. Alalawy and Z. R. Attia, *Gene*, 2025, **942**, 149259.
66. R. Basri, M. B. Aqeel, F. M. Awan, S. N. Khan, A. Obaid, R. Parveen, M. Mohsin, W. Akhtar, A. H. Shah, T. S. Afghan, A. Alam, S. Khan and A. Naz, *Sci Rep*, 2025, **15**, 3478.
67. M. Ijaz, C. C. Chen, R. K. Iqbal, H. A. Farooq, R. Mehmood, M. Asif, A. Akbar, A. Khan, W. Ijaz, M. B. Said, G. F. Wondmie, S. Ibenmoussa, M. K. Okla and F. Iqbal, *Sci Rep*, 2024, **14**, 20464.
68. R. R. Alyethodi, U. Singh, S. Kumar, R. Alex, G. S. Sengar, T. V. Raja, R. Deb and B. Prakash, *BMC biotechnology*, 2021, **21**, 36.
69. D. Lv, Y. Fan, W. Zhong, P. Lonan, K. Liu, M. Wu, Y. Wu, Y. Liang, X. Lai, G. Li and L. Yu, *Frontiers in genetics*, 2021, **12**, 632232.
70. X. Xu, X. Hu, G. Ma, T. Wang, J. Wu, X. Zhu, G. Chen, L. Zhao and J. Chen, *Heliyon*, 2023, **9**, e20159.
71. A. Qi, J. Yan, Y. Yang, J. Tang, W. Ru, X. Jiang, C. Lei, X. Sun and H. Chen, *Gene*, 2022, **838**, 146700.
72. X. C. B. G. F. W. P. Y. Z. J. and L. Y. Y., *International Food Research Journal*, 2017, **24**, 159-163.
73. A. Garcés-Claver, S. M. Fellman, R. Gil-Ortega, M. Jahn and M. S. Arnedo-Andrés, *Theor Appl Genet*, 2007, **115**, 907-916.
74. S. Qu, L. Liu, S. Gan, H. Feng, J. Zhao, J. Zhao, Q. Liu, S. Gao, W. Chen, M. Wang, Y. Jiang and J. Huang, *Clin Biochem*, 2016, **49**, 287-291.
75. A. Markou, E. Tzanikou, I. Ladas, G. M. Makrigiorgos and E. Lianidou, *Anal Chem*, 2019, **91**, 13105-13111.
76. X. Song, J. Gong, X. Zhang, X. Feng, H. Huang, M. Gao and L. Chu, *British Journal of Cancer*, 2020, **123**, 1437-1444.